Clinical

Expanding Cigna's Patient Assurance Program to include Trijardy XR

Expanding Cigna’s Patient Assurance Program to include Trijardy XR

Effective January 1, 2021, our Patient Assurance ProgramSM (PAP) now includes Trijardy XR, a medication used to treat type 2 diabetes.

Read more

Cigna's July 2020 formulary and biosimilar strategy

Cigna’s July 2020 formulary and biosimilar strategy

As part of our ongoing commitment to provide affordable and quality health care coverage, we regularly review and update our formularies. We act on research findings gleaned from integrated benefits and new drugs to market, such as biosimilars and other opportunities to reduce drug spend and improve health.

Read more

Help for opioid users thanks to utilization management tactics

Help for opioid users thanks to utilization management tactics

Cigna is committed to the fight against opioid misuse and overdose. We have set a goal to reduce overdoses among our commercial customers in key markets by 25% by December 2021.1 Our combination with Express Scripts helps strengthen our work to meet this goal.

  1. Initial focus will be on the following targeted U.S. communities where a sizable number of Cigna commercial customers reside and where there are higher incidences of overdose. These include: Connecticut, Maryland, New Jersey, Virginia, Chicago, New York City, Philadelphia, Washington, DC.

Read more

Legal Disclaimer | Privacy | Product Disclosures | Cigna Company Names

Product availability may vary by location and plan type and is subject to change. All group health insurance policies and health benefit plans contain exclusions and limitations. For costs and details of coverage, review your plan documents or contact a Cigna representative.

All Cigna products and service are provided exclusively by or through operating subsidiaries of Cigna Corporation, including Cigna Health and Life Insurance Company, (CHLIC), Evernorth Care Solutions, Inc., Evernorth Behavioral Health, Inc., Cigna Health Management, Inc., Evernorth, Accredo Health Group, Inc., Express Scripts, Inc., ESI Mail Pharmacy Service, Inc., Express Scripts Pharmacy, Inc., Tel-Drug, Inc., Tel-Drug of Pennsylvania, L.L.C., Lynnfield Drug, Inc., and HMO or service company subsidiaries of Cigna Health Corporation. Policy forms: OK - HP-APP-1 et al., OR - HP-POL38 02-13, TN - HP-POL43/HC-CER1V1 et al. (CHLIC). The Cigna name, logo, and other Cigna marks are trademarks of Cigna Intellectual Property, Inc. "Express Scripts" is a trademark of Express Scripts Strategic Development, Inc. This newsletter is not intended for residents of New Mexico.

© 2024 Cigna. All rights reserved